Principal investments include: Neutec Pharma, Isotis, Sugen, Ardana, Santaris, Xention, Gendaq, Sangamo, Acadia, Sirna, Lipid Sciences, Zeltia, Orthomimetics and Sphere Medical.
Capital market transactions include Glaxo's bid for Wellcome, Glaxo Wellcome's merger with SmithKline Beecham, the merger of Hoechst and RPR, RPR's bid for Fisons, Shire's bid for Biochem Pharma.
M&A deals involving Ambion and Cenix; Cytomyx and Millipore; Life Science Resources and Perkin Elmer.
Strategic alliances between Novartis and Microdose; Bristol Myers Squibb and QDose Technologies; NatImmune and Enzon